We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+15.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$219M
AUM Growth
+$95.8M
(+78%)
Cap. Flow
+$80.7M
Cap. Flow
% of AUM
36.91%
Top 10 Holdings %
Top 10 Hldgs %
33.7%
Holding
163
New
55
Increased
48
Reduced
23
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco DB Commodity Index Tracking Fund
DBC
|
+$32.3M |
| 2 |
AJRD
Aerojet Rocketdyne Holdings
AJRD
|
+$3.42M |
| 3 |
TXNM
TXNM Energy Inc
TXNM
|
+$3.29M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$3.26M |
| 5 |
Indivior Pharmaceuticals
INDV
|
+$2.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$4.25M |
| 2 |
Coupang
CPNG
|
+$4.1M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$3.46M |
| 4 |
TGNA
TEGNA Inc
TGNA
|
+$2.44M |
| 5 |
First Horizon
FHN
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.57% |
| 2 | Technology | 13.44% |
| 3 | Communication Services | 5.29% |
| 4 | Consumer Discretionary | 4.52% |
| 5 | Financials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Xenon Pharmaceuticals
XENE
$6.21B
| $677K | 0.31% |
17,575
-7,765
| -31% | -$309K |
|
102
NOV
NOV
$7.38B
| $675K | 0.31% |
+42,052
| New | +$685K |
|
103
Dropbox
DBX
$7.52B
| $674K | 0.31% |
+25,290
| New | +$576K |
|
104
TSMC
TSM
$2.17T
| $674K | 0.31% |
+6,675
| New | +$621K |
|
105
Teck Resources
TECK
$32.8B
| $672K | 0.31% |
15,962
+6,812
| +74% | +$293K |
|
106
New York Times
NYT
$10.5B
| $663K | 0.3% |
+16,837
| New | +$640K |
|
|
EXE
107
Expand Energy Corp
EXE
$22.6B
| $662K | 0.3% |
7,916
+3,526
| +80% | +$281K |
|
108
Alibaba
BABA
$317B
| $655K | 0.3% |
7,857
+5,197
| +195% | +$455K |
|
109
Warner Music
WMG
$13.8B
| $646K | 0.3% |
+24,779
| New | +$686K |
|
110
Madrigal Pharmaceuticals
MDGL
$11.9B
| $646K | 0.3% |
2,796
| – | – |
|
|
KALV
111
DELISTED
KalVista Pharmaceuticals
KALV
| $626K | 0.29% |
+69,567
| New | +$641K |
|
112
Pliant Therapeutics
PLRX
$64.4M
| $617K | 0.28% |
34,035
| – | – |
|
113
Crinetics Pharmaceuticals
CRNX
$8.93B
| $588K | 0.27% |
32,623
-15,622
| -32% | -$312K |
|
114
Sarepta Therapeutics
SRPT
$1.81B
| $573K | 0.26% |
5,005
-2,708
| -35% | -$349K |
|
|
MRTX
115
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $569K | 0.26% |
15,738
| – | – |
|
116
Kura Oncology
KURA
$874M
| $558K | 0.26% |
52,787
+23,545
| +81% | +$278K |
|
117
Constellium
CSTM
$3.98B
| $511K | 0.23% |
+29,694
| New | +$456K |
|
118
Autoliv
ALV
$8.92B
| $497K | 0.23% |
5,844
+3,644
| +166% | +$316K |
|
119
BioCryst Pharmaceuticals
BCRX
$2.51B
| $484K | 0.22% |
+68,725
| New | +$552K |
|
120
Iovance Biotherapeutics
IOVA
$2.9B
| $468K | 0.21% |
+66,526
| New | +$476K |
|
121
Prothena Corp
PRTA
$468M
| $437K | 0.2% |
6,406
-8,166
| -56% | -$527K |
|
122
Li Auto
LI
$12.6B
| $420K | 0.19% |
+11,966
| New | +$337K |
|
123
Relay Therapeutics
RLAY
$4.37B
| $404K | 0.19% |
32,197
-97,048
| -75% | -$1.21M |
|
124
Pinduoduo
PDD
$132B
| $403K | 0.18% |
+5,831
| New | +$401K |
|
125
Geron
GERN
$949M
| $394K | 0.18% |
+122,704
| New | +$349K |
|
Similar funds
SIAG
MS
WI
WTFG
VIA
A6
PI
ACM
HighVista Strategies's Q2 2023 Portfolio in Review
As of Q2 2023, HighVista Strategies held 163 positions worth $219M, up 78% from $123M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
HighVista Strategies deployed $80.7M of net new capital in Q2 2023, opening 55 new positions and adding to 48 existing holdings. Its largest new stake was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 67% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.75M trimmed.
- HighVista Strategies's largest Q2 2023 buy was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
- HighVista Strategies added most to Invesco DB Commodity Index Tracking Fund in Q2 2023, an estimated $32.3M increase.
- HighVista Strategies's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $1.75M.
- HighVista Strategies fully exited iShares Russell 1000 Value ETF in Q2 2023, selling an estimated $4.25M.
- HighVista Strategies's ten largest holdings make up 34% of its $219M portfolio in Q2 2023.
- HighVista Strategies opened 55 new positions and closed 29 in Q2 2023.
- HighVista Strategies's portfolio value rose 78% quarter-over-quarter to $219M.
Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.